Medical outcomes and antimicrobial costs with the use of theamerican thoracic society guidelines for outpatients with community-acquired pneumonia

JAMA

Volumn 278, Issue 1, 1997, Pages 32-39

  Gleason, Patrick P ^a,b   Kapoor, Wishwa N ^b   Stone, Roslyn A ^a,b   Lave, Judith R ^a,b   Obrosky, Scott ^b   Schulz, Richard ^c   Singer, Daniel E ^d   Coley, Christopher M ^d   Marrie, Thomas J ^e   Fine, Michael J ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c University Center for Social and Urban Research   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFACLOR; CEFALEXIN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; PENICILLIN V; TETRACYCLINE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDICATION; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT CODING; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0030982156     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.1.32     Document Type: Article

References (42)

1. Medicare and Medicaid statistical supplement, 1995. Health Care Financ Rev. September 1995:16.
2. Rodnick JE, Gude JK. Diagnosis and antibiotic treatment of community-acquired pneumonia. West J Med. 1991;154:405-409.
3. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact. Am J Med. 1985;78:32-37.
4. Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med. 1986;78: 45-51.
5. McGrew RE. Encyclopedia of Medical History. New York, NY: McGraw-Hill Book Co; 1985.
6. 1996 Redbook. Montvale, NJ: Medical Economics Data Inc; 1996.
7. Gilbert K, Kapoor WN, Marrie TJ, et al. Variation in antibiotic use and costs in patients with community-acquired pneumonia. J Gen Intern Med. 1994;9:53.
8. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet. 1987;1:671-674.
9. Ortqvist A. Antibiotic treatment of community-acquired pneumonia in clinical practice: a European perspective. J Antimicrob Chemother. 1995;35:205-212.
10. Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet. 1993;341:511-514.
11. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 1995;273:214-219.
12. Neu HC. The crisis in antibiotic resistance. Science. 1992;257:1064-1073.
13. Niederman MS, Bass JB, Campbell GD, et al. American Thoracic Society guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418-1426.
14. Fein AM, Niederman MS. Guidelines for the initial management of community-acquired pneumonia: savory recipe or cookbook for disaster? Am Respir Crit Care Med. 1995;152:1149-1153.
15. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333:1618-1624.
16. Conducting medical effectiveness research: a report from the inter-PORT work groups. Med Care. 1994;32:1-12.
17. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, Mass: The Health Institute; 1993.
18. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Summary Scales: User's Manual. Boston, Mass: The Health Institute; 1994.
19. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implication for therapy: a prospective multicenter study of 359 cases. Medicine. 1990;69:307-316.
20. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336: 243-250.
21. Minogue MF, Coley CM, Hough LN, et al. Patients hospitalized after initial ambulatory therapy for community acquired pneumonia. J Gen Intern Med. 1996;11:52.
22. 1993 Redbook. Montvale, NJ: Medical Economics Data Inc; 1993.
23. Tenover FC, McGowan JE Jr. Reasons for the emergence of antibiotic resistance. Am J Med Sci. 1996; 311:9-16.
24. Fass RJ. Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J Antimicrob Chemother. 1993;32:17-27.
25. Jernigan DB, Cetron MS, Breiman RF. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). JAMA. 1996;275:206-209.
26. Sankilamp U, Herva E, Haikala R, Limatainen O, Renkonen OV, Leinonen M. Epidemiology of invasive Streptococcus pneumoniae infections in adults in Finland. Epidemiol Infect. 1997;118:7-15.
27. Marrie TJ. Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly. Arch Intern Med. 1993;153: 488-494.
28. Erard PH, Moser F, Wenger A, Saghafi L, et al. Prospective study of community-acquired pneumonia diagnosed and followed up by private practitioners. In: Program and abstracts of the 1991 Inter-science Conference on Antimicrobial Agents and Chemotherapy; September 29-October 2, 1991; Chicago, Ill. Abstract 56:108.
29. Macfarlane J. An overview of community-acquired pneumonia with lessons learned from the British Thoracic Society. Semin Respir Infect. 1994; 9:153-165.
30. Shaw AB, Fry J. Acute infections of the chest in general practice. BMJ. 1955;2:1577-1586.
31. Everett MT. Major chest infections managed at home. Practitioner. 1983;277:1743-1754.
32. Dulake C, Selkon J. The incidence of pneumonia in the UK. In: Pneumonia and Pneumococcal Infections. London, England: Royal Society of Medicine; 1982:87-94. Symposium Series No. 27.
33. Mardh P, Hovelius B, Nordenfelt E, Rosenberg R, Soltesz LV. The incidence and aetiology of respiratory tract infections in general practice: with emphasis on Mycoplasma pneumoniae. Infection. 1976;4(suppl 1):40-48.
34. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med. 1996; 101:508-515.
35. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis. 1989;11:586-599.
36. Ortqvist A, Sterner G, Nilsson JA. Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis. 1985;17:377-386.
37. Torres A, Serra-Batlles J, Ferrer A, Ferrer A, Jimenez P, Celis R. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis. 1991;144:312-318.
38. Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia: etiology, prognosis, and treatment. Am Rev Respir Dis. 1990;142:369-373.
39. Bates JH, Campbell GD, Barron AL, et al. Microbial etiology of acute pneumonia in hospitalized patients. Chest. 1992;101:1005-1012.
40. British Thoracic Society Research Committee and the Public Health Laboratory Service. The aetiology, management and outcome of severe community-acquired pneumonia in the intensive care unit. Respir Med. 1992;86:7-13.
41. Hayward RSA, Wilson MC, Tunis SR, Bass EB, Guyatt G. Users' guides to the medical literature, VII: how to use clinical practice guidelines, A: are the recommendations valid? JAMA. 1995;274:570-574.
42. Selker HP. Criteria for adoption in practice of medical practice guidelines. Am J Cardiol. 1993;71: 339-341.